The Core Difference: Selectivity
Anabolic-androgenic steroids (AAS) are non-selective androgen receptor agonists — they bind to androgen receptors throughout the body including muscle, bone, prostate, liver, hair follicles, sebaceous glands and the HPTA. This lack of selectivity is what drives the well-documented side effect profile of AAS.
SARMs (Selective Androgen Receptor Modulators) were developed specifically to be tissue selective — binding to androgen receptors primarily in muscle and bone while having minimal activity in tissues like the prostate and liver. This selectivity is the core research hypothesis.
⚠ Research Purposes Only: Both SARMs and anabolic steroids discussed on this page are research chemicals or controlled substances. Nothing on this page constitutes advice to use either class of compound.
Head-to-Head Research Comparison
| Factor | Anabolic Steroids | SARMs |
|---|---|---|
| AR Selectivity | Non-selective (all tissues) | Tissue-selective (muscle/bone focus) |
| HPTA Suppression | Severe | Moderate (dose-dependent) |
| Liver Toxicity | High (oral 17α-alkylated) | Low–Moderate (oral SARMs) |
| Prostate Effects | Significant stimulation | Minimal in research models |
| Hair Loss Risk | High (DHT conversion) | Lower (no/minimal DHT conversion) |
| Cardiovascular Impact | Significant HDL/LDL effects | Less studied, some lipid effects noted |
| Legal Status (USA/UK) | Schedule III (USA) / Class C (UK) | Research chemical (unscheduled in most areas) |
Does the Selectivity Research Hold Up?
The selectivity claim for SARMs is supported by preclinical and limited clinical data. Published Phase I trials for RAD-140 and LGD-4033 do show significantly less androgenic side effects compared to historical AAS data at anabolically effective doses. However, SARMs are not perfectly selective — suppression still occurs, and cardiovascular effects (particularly HDL reduction) have been documented.
Clinical Data Comparison
| Compound | Class | Human Trial Status | Lean Mass Gain (21–84 days) |
|---|---|---|---|
| LGD-4033 (1mg/day) | SARM | Phase I complete | ~1.2 kg (21 days) |
| Testosterone (600mg/week) | AAS | Extensive clinical data | ~6.1 kg (10 weeks) |
| RAD-140 | SARM | Phase I complete | Data pending publication |
The comparison illustrates the trade-off: SARMs show more modest anabolic effects in published research compared to supraphysiological AAS doses, but with substantially reduced androgenic side effect burden at the doses studied.
🔬 Where to Source SARMs for Research (USA & UK)
For USA and UK researchers, BehemothLabz is one of the most reliable sources with third-party certificates of analysis. All products are for research purposes only and not approved for human consumption.
Visit BehemothLabz →⚠ Affiliate link — use code Tomjunkie for 20% off. Research purposes only.
Frequently Asked Questions
Published research suggests SARMs have a significantly reduced androgenic side effect profile compared to anabolic steroids at the doses studied in clinical trials. However, SARMs are not risk-free — HPTA suppression and lipid effects have been documented. Both are research chemicals only.
SARMs are not 17α-alkylated like many oral anabolic steroids, which is associated with hepatotoxicity. Clinical trials for LGD-4033 and RAD-140 did not show significant liver toxicity markers, though liver monitoring is standard in research protocols.
Yes. Published Phase I trials show dose-dependent HPTA suppression with SARMs. Recovery is observed post-discontinuation in research studies. Suppression is less severe than with anabolic steroids but is not absent.
SARMs are unscheduled research chemicals in most US states and in the UK, but are banned by WADA for competitive sport. Legal status is distinct from safety or approval — they are not approved for human consumption by the FDA or MHRA.